Presentation is loading. Please wait.

Presentation is loading. Please wait.

Genomics in Drug Organon, Oss 2005-08-22 Tim Hulsen.

Similar presentations


Presentation on theme: "Genomics in Drug Organon, Oss 2005-08-22 Tim Hulsen."— Presentation transcript:

1 Genomics in Drug Discovery @ Organon, Oss 2005-08-22 Tim Hulsen

2 Introduction Proteins are vital to life: involved in all kinds of life processes Understanding protein functions and relationships is very important for drug design Currently, the molecular function of about 40% of the proteins is unknown

3 Introduction Determine protein function by using different in silico techniques: sequence comparison to known protein sequences sequence clustering with proteins which have the same or similar function Availability of fully sequenced genomes gives us a wealth of information: currently more than 15 eukaryotic genomes have nearly been completely sequenced, over 148 microbial genomes and over 1000 viruses.

4 Genomics @ Organon: The Protein World project All-against-all sequence comparison of complete proteomes from 145 species Smith-Waterman algorithm + Z-value (Monte-Carlo statistics)

5 Protein World and its ambitions Build and maintain a sequence similarity repository of all complete proteomes and aligning it with “omics” research in the Netherlands Classification of all proteins into groups of related proteins A phylogenetic repository Annotation of new sequences Mining protein families Identification of genes common / specific to (groups of) species

6 Applications of Protein World Structural properties Protein comparison coupled to structure related databases (PDB, SCOP, etc.) Systems biology Connecting PW to other databases (pathways, protein interactions, literature etc.) Orthology Annotation of new proteins To predict discrepancies and similarities between species

7 Orthology Describes “the evolutionary relationship between homologous genes whose independent evolution reflects a speciation event” (Fitch, 1970)

8 Protein World & Drug Discovery Orthologies can be used to transfer function of proteins in model organisms (mice, rats, dogs, etc.) to humans Drugs tested on model organisms can have different effects in humans. Why? Could be explained by looking at proteins in drug pathways and their orthologs Example: trypsin inhibition pathway

9 Trypsin inhibition pathway (1) Organon: thrombin inhibitors Needed to stop thrombosis (blood clotting) Thrombin inhibitor on the market: (xi)melagatran, sold as Exanta (AstraZeneca) Proven to be better than warfarin, but …

10 Trypsin inhibition pathway (2) Side effect of thrombin inhibitors: inhibition of trypsin Trypsin inhibition -> rise in cholecystokinin (CCK) levels -> stimulation of pancreas -> pancreatic tumors Difficult to test in model organisms: –Rat: very strong CCK response –Mouse: weak CCK response –Human: almost no CCK response

11 Trypsin inhibition pathway (3)

12 Trypsin inhibition pathway (4) Ortholog identification methods: 1.Using functional annotation (SPTrEMBL): 2.Best Bidirectional Hit (BBH)  one-to-one relationships 3.PhyloGenetic Trees (PGT)  many-to-many relationships

13 Best Bidirectional Hit (BBH) Very easy and quick Human protein (1)  SW  best hit in mouse/rat (2) Mouse/rat protein (2)  SW  best hit in human (3) If 3 equals 1, the human and mouse/rat protein are considered to be orthologs

14 PhyloGenetic Tree (PGT) Human All eukaryotic proteomes Z>20 RH>0.5*QL ~25,000 groups PHYLOME SELECTION OF HOMOLOGS ALIGNMENTS AND TREES PROTEOME PROTEOMES TREE SCANNING LIST Hs-Mm pairs Hs-Rn pairs

15 Trypsin inhibition pathway (5) Mm – Hs – Rn - by annotation - BBH - PGT

16 Trypsin inhibition pathway (6) PGT method: in some cases too many orthologous relationships, especially for trypsin (73 in mouse and 62 in rat!) BBH method seems to be more usable for this study, but still not gives an explanation for the differences in CCK levels Our problem (different CCK responses in Human, Mouse and Rat) cannot be solved only by orthology identification  Combine ortholog analysis with other data  Focus on the molecules that are most likely to be responsible for these differences: CCK and trypsin

17 Trypsin inhibition pathway (7) Current activities: –Take a better look at regulation: promoter detection? –Use expression data? –Structural explanation? Modelling of interactions between the involved molecules

18 Possible student projects Orthology case study: explain differences between humans and model organisms (like example of trypsin inhibition pathway) Chicken project (in collaboration with Wageningen University): comparison of immune system in chickens to i.s. in humans and other vertebrates Cluster algorithms

19 People Peter Groenen Wilco Fleuren Tim Hulsen Others @ MDI Students?


Download ppt "Genomics in Drug Organon, Oss 2005-08-22 Tim Hulsen."

Similar presentations


Ads by Google